Clinical Report: Assessment of Global Skin Cancer Impact from 1990 to 2023
Background
Malignant skin cancers represent a growing global health concern, with rising incidence rates and significant morbidity. Understanding the epidemiological trends and projections is crucial for healthcare planning and resource allocation. This report highlights the disparities in skin cancer burden across different regions and socioeconomic contexts.
Data Highlights
Skin Cancer Type
2023 Prevalence (cases per 100,000)
Projected DALYs in 2050
Melanoma
Oceania: >300
3.3 million
Squamous Cell Carcinoma
US: >200
4.0 million
Basal Cell Carcinoma
Oceania: >200, North America: >150, Northern Europe: >100
5.0 million
Key Findings
From 1990 to 2023, melanoma incidence increased by 258.8% in East Asia and 274.6% in Andean Latin America.
High-income North America saw a 10.5% decrease in melanoma incidence, while squamous cell carcinoma and basal cell carcinoma increased by 154.1% and 34.6%, respectively.
Male prevalence rates for melanoma were higher than females, with 28.2 cases per 100,000 in males versus 25.6 in females in 2023.
DALYs for melanoma declined in high-SDI regions, while squamous cell carcinoma DALYs increased by 93.2% in low-SDI settings.
Projections indicate significant increases in DALYs for all skin cancers by 2050, particularly in low- and middle-SDI regions.
Clinical Implications
Healthcare professionals should be aware of the increasing burden of skin cancers, particularly in low- and middle-SDI regions. This necessitates targeted prevention and treatment strategies to address the rising incidence and associated morbidity.
Conclusion
The findings highlight the urgent need for public health interventions and resource allocation to manage the growing burden of skin cancers globally, especially in vulnerable populations.
